Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
路透社2026/10/08 12:56The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Stock information has been added in the second paragraph, detailed information has been added in the fifth, eighth, and ninth paragraphs, and background information has been added in the sixth, seventh, tenth, and eleventh paragraphs.
Reuters, October 8 - Pharmaceutical company Viatris VTRS.O will acquire Pacira BioSciences PCRX.O in an all-cash deal valued at $1.65 billion, adding two non-opioid pain medications to its portfolio, the two companies announced on Thursday.
Viatris will acquire Pacira for $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s shares rose 44% in premarket trading.
Pacira’s non-opioid pain medications, Exparel and Zilretta,
had 2025 sales of $575.1 million and $116.6 million, respectively. Exparel is used for the treatment of acute post-surgical pain, while Zilretta is used to treat pain associated with knee osteoarthritis.
Viatris said it expects to expand the reach of these products in certain target markets.
Viatris CEO Scott Smith stated in a press release that the addition of these drugs “creates synergy with the market opportunity for our rapid-onset meloxicam and positions us as a leader in the non-opioid pain treatment field.”
The U.S. Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-onset meloxicam to treat moderate to severe acute pain.
Viatris plans to primarily fund this acquisition with available cash, with the remainder raised via short-term borrowing. The company stated the transaction has a minimal impact on its total leverage ratio.
In August, Viatris (link) raised its annual adjusted profit forecast, as it counted on strong sales of branded drugs and growth in the Chinese market.
The pharmaceutical company previously faced setbacks in its Indian operations (link), including manufacturing issues such as a fire at its plant in Nashik, western India, and intensifying competition in the generic drug market, raising concerns over the growth and resilience of its core business.
The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics.
(For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of translated texts. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss that may result from using the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 1 - The Financial Times reports that Starbucks once considered acquiring Chipotle
Reuters reported on October 8, citing sources from the Financial Times, that Starbucks (SBUX.O) had explored the possibility of acquiring Chipotle Mexican Grill (CMG.N). As background, Starbucks CEO Brian Niccol previously led Chipotle and is widely credited with transforming the burrito chain into one of the strongest growth companies in the industry. Both Starbucks and Chipotle did not immediately respond to Reuters' request for comment. Starbucks, with a market capitalization of around $39 billions, saw its share price decline by about 3%, while Chipotle’s stock price rose by approximately 4%.
BUZZ - Goldman Sachs turns bullish, Palantir shares rise
On October 8th, Palantir Technologies (stock code: PLTR.O), a data analytics software provider, saw its shares rise by 3.7% to $201.26 in early trading Thursday, after Goldman Sachs upgraded its rating from “Neutral” to “Buy.” The firm set a target price of $230, representing approximately an 18% upside from the previous trading day’s closing price. Goldman Sachs stated that, based on recent discussions with industry experts, its main conclusion is that the stock is expected to enter a new phase of outperformance before 2027. The bank noted that with PLTR shifting towards sovereign AI, customized applications, and its new verticalization strategy, its total addressable market “may be on the verge of another step-change in depth.” Goldman Sachs also mentioned that, given the stock’s underperformance in 2026, its enterprise value/free cash flow (EV/FCF) multiple is currently lower than that of peer growth companies. With Thursday’s rally, PLTR’s share price has increased about 13% this year, lagging behind the Nasdaq .IXIC index’s 18% gain; the current price is about 3% lower than the all-time intraday high of $207.52 set on November 3, 2025. According to LSEG data, among the 33 brokers covering the stock, 24 rate it as “Strong Buy” or “Buy,” 7 as “Hold,” and 2 as “Sell” or “Strong Sell.” The median target price is $212.50, up from $195 three months ago. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translation may be inaccurate or may not capture the needed context, and Reuters does not guarantee the accuracy of automated translation. Automated translation is provided solely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Germany: Gradual recovery with energy risks – Deutsche Bank

BUZZ - JPMorgan downgrades HubSpot rating due to "uncertain outlook" amid recovery in revenue growth
On October 8, JPMorgan downgraded its rating for marketing software company HubSpot (HUBS.N) from “Overweight” to “Neutral,” and also lowered its price target from $268 to $240, which still represents a 23.6% upside from the previous trading day’s closing price. The report pointed out that the timeline for a recovery in revenue growth is “still unclear.” “Although HUBS shares have fallen by more than 40% so far this year, until there are clear signs that the growth slowdown has bottomed out, we do not expect to see renewed investor interest or a significant re-rating of the stock price,” said JPMorgan. Out of 37 brokerages, 13 rate the stock as “Buy” or higher, 23 as “Hold,” and 1 as “Sell”; the median price target is $250, according to Reuters compiled data. Including fluctuations on the day, the stock has declined by 45.2% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be incorrect or lack the intended context; Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters assumes no liability for any damages or losses arising from the use of automated translation features.)